|
CAS-Nr. | 444731-52-6 |
Bezeichnung: | |
Englisch Name: | Pazopanib |
Synonyma: | Votrient;Pazopanib;Pazopanib base;Pazopanib(GW786034);Votrient(pazopanib);Pazopanib for research;5-[[4-[(2,3-DiMethyl-2H-indazol-6-yl)MethylaMino]-2-pyriMidinyl]aMino]-2-Methyl-benzenesulfonaMide;5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide;BenzenesulfonaMide, 5-[[4-[(2,3-diMethyl-2H-indazol-6-yl)MethylaMino]-2-pyriMidinyl]aMino]-2-Methyl-;5-[(4-{[(2,3-diMethyl-2H-indazol-6-yl)Methyl]aMino}pyriMidin-2-yl)aMino]-2-Methylbenzene-1-sulfonaMide |
CBNumber: | CB91562449 |
Summenformel: | C21H23N7O2S |
Molgewicht: | 437.52 |
MOL-Datei: | 444731-52-6.mol |
|
|
|
|
Pazopanib physikalisch-chemischer Eigenschaften |
Schmelzpunkt:: |
285-289°C (dec.) |
|
|
storage temp. : |
Refrigerator |
|
|
Pazopanib Chemische Eigenschaften,Einsatz,Produktion Methoden |
Chemische Eigenschaften Off-White Solid |
|
Verwenden Pazopanib Hydrochloride (GW786034, Votrient, Armala) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM, respectively. |
|
Verwenden Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR-α/β, and c-Kit. |
|
Verwenden Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM, respectively. |
|
Verwenden An oral angiogenesis inhibitor targeting VEGFR and PDGFR. |
|
|
Pazopanib Upstream-Materialien And Downstream Produkte |
Upstream-Materialien
|
Downstream Produkte
|
Pazopanib Anbieter Lieferant Produzent Hersteller Vertrieb Händler. Global( 116)Lieferanten |
|
|
|
|
444731-52-6
Pazopanib for research
5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide
Pazopanib
C21H23N7O2S
Pazopanib(GW786034)
Intermediates & Fine Chemicals
Pharmaceuticals
5-(4-((2,3-diMethyl-3,3a-dihydro-2H-indazol-6-yl)(Methyl)aMino)pyriMidin-2-ylaMino)-2-MethylbenzenesulfonaMide
5-[(4-{[(2,3-diMethyl-2H-indazol-6-yl)Methyl]aMino}pyriMidin-2-yl)aMino]-2-Methylbenzene-1-sulfonaMide
5-({4-[(2,3-diMethyl-2H-indazol-6-yl)(Methyl)aMino]pyriMidin-2-yl}aMino)-2-MethylbenzenesulfonaMide
5-(4-(N-(2,3-diMethyl-2H-indazole-6-yl)- N-MethylaMino)pyriMidine-2-ylaMino)-2-MethylbenzenesulfonaMide
HFC80010
Votrient
5-[[4-[(2,3-DiMethyl-2H-indazol-6-yl)MethylaMino]-2-pyriMidinyl]aMino]-2-Methyl-benzenesulfonaMide
BenzenesulfonaMide, 5-[[4-[(2,3-diMethyl-2H-indazol-6-yl)MethylaMino]-2-pyriMidinyl]aMino]-2-Methyl-
Pazopanib base
5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide Pazopanib
Pazopanib 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide
Votrient(pazopanib)
|